Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

Multivessel PCI Helps Most in STEMI Patients With Severe Nonculprit Lesions

Todd Neale

September 11, 2020

News Features

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

Michael O'Riordan

December 12, 2019

News Daily News

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Shelley Wood

October 14, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Daily News

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Yael L. Maxwell

January 12, 2015

News Conference News

PROTECTION-AMI: Experimental Agent Does Not Prevent Reperfusion Injury

Caitlin E. Cox

April 05, 2011

Advertisement

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Multivessel PCI Helps Most in STEMI Patients With Severe Nonculprit Lesions

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Discussion Highlights Merits, Limitations of Small Trials

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

PROTECTION-AMI: Experimental Agent Does Not Prevent Reperfusion Injury

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content